L-Phenylalanine restriction amplifies boron neutron capture therapy efficacy through increased L-boronophenylalanine uptake and induces activating transcription factor 4 stress response in tumor cell lines
Yuki Tamari, Rie SabaiD, Takushi TakataiD, Hiroyuki Kimura, Mao Takita, Kenta YashiroiD, Minoru SuzukiiD, Hideya YamazakiiD, Kei YamadaiD
Abstract
Boron neutron capture therapy (BNCT) relies on the selective uptake of boron-10 compounds by tumor cells. L-boronophenylalanine (BPA) serves as a key carrier, and enhancing its accumulation is critical for improving BNCT efficacy. In this study, we investigated the effects of L-phenylalanine (Phe) restriction on the tumor cell lines SAS, U87-MG, PANC-1, and A375, and the immortalized keratinocyte line HaCaT on modulating BPA uptake and associated cellular responses. Quantitative analysis using inductively coupled plasma atomic emission spectroscopy (ICP-AES) showed that 24 h Phe restriction increased BPA uptake in the SAS, U87-MG, and PANC-1 cell lines. Colony formation assays confirmed enhanced sensitivity to neutron irradiation in these cells. RNA sequencing indicated that Phe restriction activated the integrated stress response downstream of activating transcription factor 4 (ATF4), although this pathway was not directly linked to increased BPA uptake. The L-type amino acid transporter 1 (LAT1)/4F2 heavy chain (4F2HC) complex was identified as the exclusive transport route for BPA. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis showed that Phe restriction altered intracellular levels of amino acids that serve as LAT1/4F2HC exchange substrates, suggesting a metabolic basis for enhanced BPA transport. Our results reveal that Phe restriction enhances BPA uptake and BNCT efficacy in a cell line-dependent manner, likely through the modulation of amino-acid metabolism. Therefore, targeted amino-acid manipulation prior to BNCT may represent a promising strategy to improve therapeutic outcomes.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 0
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Boosting Antitumour Efficacy and Immunity by Boron Neutron Capture Therapy with Size-Controlled Nanoparticles
Weian Huang, Heon Gyu Kang, … Naoki Komatsu·bioRxiv·Apr 2, 2025
- The First Experience of Accelerator-based Lithium Neutron Capture Therapy in vivo
Iuliia S. Taskaeva, А. I. Kasatova, … Sergey Yu. Taskaev·bioRxiv·Sep 8, 2026
- BNCT Triggers Immunogenic Cell Death in B16 Melanoma Without Accompanying T-Cell Infiltration--Implications for Combination Immunotherapy
Rui Quan, Hefa Huang, … Long Gu·bioRxiv·Nov 5, 2026
- Bone marrow-derived macrophages loaded with boron carbide nanoparticles as selective boron carriers for crossing the blood-brain barrier toward the glioma microenvironment for boron neutron capture therapy
Anna Rudawska, Agnieszka Szczygieł, … Bożena Szermer-Olearnik·bioRxiv·Jan 10, 2026
- Low-dose radiopharmaceutical therapy enhances the efficacy of B7-H3 CAR T cells in murine metastatic neuroblastoma
Amanda G. Shea, Andrew Ollendorff, … Quaovi H. Sodji·bioRxiv·Sep 24, 2026
- Pharmacological inhibition of the amino-acid transporter LAT1 demonstrates in vitro anti-neoplastic activity towards medulloblastoma
Y. Cormerais, M. Pagnuzzi-Boncompagni, … V. Picco·bioRxiv·Jan 8, 2019